The Trend Is Your Friend

trenfriend

There are trading phrases that survive because they are useful, and there are trading phrases that survive because they are easy to repeat. “The trend is your friend” belongs to both categories. It is useful, but only when treated as a probabilistic framework rather than a religious commandment. Used well, it keeps a trader aligned with momentum, liquidity, and market psychology. Used badly, it turns into a license to chase, overstay, and confuse a mature move with a fresh opportunity.

A World on Edge

There are days when the future feels distant, theoretical, something that belongs to policy papers and conference panels. Then there are days when the future stops waiting politely and arrives all at once. April 11, 2026 feels like one of those days. The geopolitical map is unstable, supply chains are once again hostage to geography, financial markets are discovering that volatility is not a passing phase, and the labor market is beginning to absorb the first serious psychological shock from artificial intelligence.

Voyager Technologies (NYSE: VOYG) — April 2026 deep dive

Voyager Technologies is one of the more interesting space-defense names because it is not a clean, single-theme stock. It is not just a commercial space dream. It is not just a defense contractor. It is not just a speculative “future station” vehicle either. It is a hybrid company where a real operating business in defense and mission services sits next to a very large long-duration bet on the future commercial low-Earth-orbit economy. That mix is what makes VOYG potentially powerful, but it is also exactly what makes it difficult to value.

Celldex Therapeutics (CLDX): the full April 2026 deep dive on barzolvolimab, pipeline breadth, financing, competition and what still has to go right

This is our first full Merlintrader deep dive on CLDX. The core of the story is simple: Celldex is being valued primarily as a barzolvolimab company, but the real debate is whether barzolvolimab can move from an unusually strong phase 2 setup into a durable commercial immunology franchise across CSU, inducible urticarias and potentially additional inflammatory skin diseases.

POET Technologies ( $POET ) — April 2026 deep dive

From narrative-rich AI photonics story to execution test: POET now has a far bigger balance sheet, a broader partnership map and a clearer 2026–2027 roadmap — but the market still wants the same proof as always: real shipments, repeat revenue and evidence that the Optical Interposer can scale outside press releases.

Replimune after the second CRL: why RP1 was stopped again, what still stands, and where the IOVA comparison truly fits

The FDA’s second no on RP1 plus nivolumab in advanced melanoma does not look like a simple administrative delay. It is a rejection that hits the core regulatory thesis, reopens the debate around the program’s near-term value and forces a broader reassessment of the Replimune story as a strategic reset rather than a delayed approval thesis.

Vera Therapeutics (VERA): April 2026 Deep Dive

Vera has moved from a pure data story into a real pre-commercial FDA story. The old thesis was about whether atacicept could produce strong enough renal data to justify a major rerating. The April 2026 thesis is narrower and more demanding: can Vera convert strong upstream biology, a clean Phase 3 interim package and a differentiated at-home profile into approval, a credible first launch, and a durable place in an IgAN market that is no longer empty?

SoFi after the hype reset: profitable scale, a bigger platform ambition, and the real debate on valuation

This April update revisits SoFi with fresh context after the Q4 2025 numbers, the March short-seller clash, the expansion of the Loan Platform Business, and the launch of Big Business Banking. The core question is no longer whether SoFi can grow; it is whether the market is looking at a durable multi-engine financial platform or still at a premium-priced lender with more execution risk than bulls admit.

United States Antimony ( $UAMY ): April 2026 update on earnings, Gary Evans, new projects, and the real execution test ahead

UAMY is no longer just a tiny legacy smelter story. After a violent 2025 growth year, the company now sits at the intersection of domestic critical-minerals policy, military antimony demand, vertical integration ambitions, and an increasingly complex balance sheet. The market narrative has become much bigger, but the same question now matters even more: can management turn a promotional national-security story into durable, cash-generating industrial execution?

Verrica Pharmaceuticals (VRCA): deep dive 2026 after the balance-sheet reset, the YCANTH ramp and the renewed VP-315 scientific story

VRCA is no longer a simple one-product dermatology story. The company now combines a real commercial base in YCANTH, a large common-warts expansion opportunity with unusually helpful cost-sharing economics, and a basal cell carcinoma asset in VP-315 that continues to add regulatory and scientific credibility. The stock still carries the usual small-cap biotech risks, but the narrative is broader and more interesting than the older “just molluscum and financing stress” version.

Milestone Pharmaceuticals ( $MIST ) — from approval to execution

The key change since the December 2025 approval is simple: the stock is no longer being judged mainly on whether CARDAMYST can reach the market, but on whether Milestone can actually turn that approval into real access, real prescriptions, real repeat physician behavior, and eventually a broader etripamil franchise beyond PSVT. That sounds less dramatic than a PDUFA setup, but it is usually the more important phase. Approval can rerate a story for a week. Commercial traction is what can rerate it for much longer.

ImmunityBio (IBRX): from the FDA advertising warning to the company’s fix plan, lawsuit noise, and stronger early Q1 revenue

IBRX APRIL

This update picks up the story where the earlier Merlintrader pieces left it: global expansion, label-expansion ambition and clinical momentum were still moving forward, but the market narrative suddenly shifted when the FDA’s Office of Prescription Drug Promotion publicly challenged how ANKTIVA had been promoted. The key question now is not whether the issue existed — it did — but whether the company’s remediation plan is enough to contain the damage while the underlying commercial story keeps improving.

UiPath ( $PATH ): from classic RPA leader to agentic automation platform

This deep dive looks at where UiPath stands now after fiscal 2026 results, the strategic shift toward agentic automation, the current balance between improving profitability and still-moderate growth, the state of the balance sheet and buyback, the role of Daniel Dines and governance, what institutions and analysts are likely watching, how retail sentiment is split, and what a realistic bull and bear framework looks like from here.

PMGC Holdings (NASDAQ: $ELAB) — update deep dive April 2026

ELAB is no longer just a tiny “obesity + AI + low float” story. Since the prior Merlintrader article, the company has added another manufacturing asset, widened the NorthStrive pipeline, opened a new defense-tech lane, and fully tapped a $20 million Streeterville facility. That gives it more operational breadth, but it also hardens the core problem: cash is less immediate, dilution is more real, and execution now has to work across biotech, industrial integration and defense optionality at the same time.

Applied Digital (APLD) — Deep Dive April 2026

Applied Digital is one of the more interesting infrastructure stories in the market because it sits at the intersection of three forces that investors have spent the last year chasing aggressively: hyperscaler demand, power scarcity, and the belief that the economic winners of the AI cycle will not only be the model builders but also the owners of the physical capacity that makes those workloads possible. That is the seductive version of the story, and it is easy to understand why it caught such a bid.